Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frazier LifeSciences

- PMLiVE

NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

- PMLiVE

NewAmsterdam shares positive phase 3 results for CETP inhibitor obicetrapib in HeFH

Heterozygous familial hypercholesterolaemia affects approximately one in 250 people globally

- PMLiVE

A powerful care platform connects medical professionals and patients

Education platforms that disseminate the latest advances in cardiovascular medicine to cardiologists, physicians and healthcare professionals are helping deliver better outcomes for heart patients.

Medscape Education

- PMLiVE

AstraZeneca’s Farxiga data shows ‘significant’ mortality benefits in heart failure patients

The pre-specified pooled analysis from two phase 3 trials demonstrated a reduction in cardiovascular death by 14%

- PMLiVE

Over 47,000 stroke patients to miss out on ‘game-changing’ treatment, the Stroke Association warns

This year, NHS England failed to reach its original target to make mechanical thrombectomy available to all suitable patients

- PMLiVE

NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

The agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links